- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
GSK India reported strong Q1 results: Revenue up 15% to INR 924 Cr, PAT up 24% to INR 253 Cr. Growth fueled by core portfolio, innovative oncology, and vaccines. Upcoming launches include Blenrep and Arexvy.
All announcements from GlaxoSmithKline Pharmaceuticals Limited